Passive Immunization Trials to Inform Vaccine Design

Similar documents
Statistical Issues in Assessing Treatment Efficacy and Correlates of Protection in mab Efficacy Trials

Monoclonal Antibodies for Treatment and Prevention of HIV-1 CROI Charles Boucher Erasmus MC

Antibody against Chikungunya virus (mrna-1944)

ICH Considerations. Oncolytic Viruses September 17, 2009

ICH CONSIDERATIONS Oncolytic Viruses

FDA Draft Guidance on Immunogenicity Testing

ICH Considerations Oncolytic Viruses ONCOLYTIC VIRUSES (EMEA/CHMP/ICH/607698/2008) TRANSMISSION TO CHMP November 2008

Predicting and Understanding HIV-1 Resistance to Broadly Neutralizing Antibodies. Anna Feldmann Max Planck Institute for Informatics

1 R01 AI VMD HALFORD, W

FDA Public Hearing: Approval Pathway for Biosimilar. Products. November 2-3, 2010

ASSESSING THE EFFICACY AND SAFETY OF NORMAL INTRAVENOUS IMMUNOGLOBULIN PRODUCTS FOR MARKETING AUTHORISATIONS

Samatasvir (IDX719), a Potent Pan-Genotypic NS5A Inhibitor, for the Treatment of Hepatitis C Virus (HCV) Infection

SUPPLEMENTARY MATERIAL. Viral variants that initiate and drive maturation of V1V2- directed HIV-1 broadly neutralizing antibodies

Pre-existing anti-viral vector antibodies in gene therapy

Biosimilar Monoclonal Antibodies: Registration Requirements. Henry M. J. Leng

Field trial with veterinary vaccine

RSV Vaccine Development Status Update

1 R21 AI A1 2 VMD HALFORD, W

Passive vaccination as a global strategy for preventing RSV disease in infants. Filip Dubovsky MD MPH FAAP MedImmune March 2016

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP)

Biosimilars China Guideline. Dr Dr Michel Mikhail

HIV VACCINE PROGRAM and P5 PARTNERSHIP

Infectious Disease Programs:

Professor Andrea Laslop, MD, Austria

Regulatory Issues and Drug Product Approval for Biopharmaceuticals

Genmab an antibody innovation powerhouse. Jan van de Winkel

Synthetic vaccine research and development. Comprehensive and innovative synthetic biology solutions and technologies

Trubion Investor Presentation BioCentury NewsMakers in the Biotech Industry Conference September 6, 2007

London, 11 October 2006 Doc. Ref. EMEA/CHMP/BWP/271475/2006 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)

Regulatory Challenges for the Licensure of Future Vaccines

Unique PK-PD properties of biotechnology-based therapeutics [mabs] and First In Human dose considerations. [mabs -monoclonal antibodies ] Peter Lloyd

Novel HIV-1 envelope proteins to induce neutralizing antibodies

Regulatory perspective on setting clinically relevant specifications. Joslyn Brunelle, PhD Team Leader Office of Biotechnology Products

MPE8 antibody hits the Achilles heel of the viruses Davide Corti

Development of plasma therapies for emerging infectious diseases. Dr Glenn Smith Biological Science Section Scientific Evaluation Branch

Fc engineering for improved developability and retained biological activity

Course Agenda. Day One

WHO Blood Regulators Network (BRN)

Revised Immunogenicity Guideline: Assays and methods- Presentation of the draft guideline and introduction of the topics for discussion

Docket #: FDA-2018-D-3268

Interchangeability: What is Next? Analysis of the concept & of the FDA Draft Guidance

Vladimir Hanes, MD, USA

Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection

Interplay of Cells involved in Therapeutic Agent Immunogenicity. Robert G. Hamilton, Ph.D., D.ABMLI Professor of Medicine and Pathology

Biomarkers, Early Prediction of Vaccine Efficacy and Safety

Oral vaccines to protect patients against Clostridium difficile infection

Identification of Critical Product Quality Attributes: Impact of Product Variants on Safety and Efficacy

INTELLIGENT ANTIBODY DISCOVERY FROM HUMANS AND OTHER ANIMALS. Guy Cavet

J.P. Morgan Healthcare Conference. January 15, 2009

ADCC and HVEM: Lessons from an HSV-2 ΔgD vaccine. Clare Burn Laboratory of Betsy Herold and Laboratory of William R. Jacobs, Jr.

Optimizing the Development of Biosimilars Using PK/PD: Recent Scientific and Regulatory Advances

EU Regulatory Perspective on RSV vaccines

Guideline for the quality, safety and efficacy of follow-on biological medicinal products

Current Considerations on Chemistry, Manufacturing and Control of Cell Therapy Products (CTPs)

Moderna Therapeutics Announces Transition to a Clinical Stage Company, Provides Business Update and Outlines 2016 Strategic Priorities

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)

NIAID Strategic Plan for Biodefense Research February 2002

Clinical qualification of specifications - a Regulator s view

Baek, Kyung-min. Recombinant Protein Products Division. Ministry of Food and Drug Safety

DRUG REGISTRATION REGULATION

Development of Multiplex Sensitive Anti-Drug Antibody Assays for CRISPR/Cas9 Gene Therapies

Sangamo Therapeutics Announces Presentations at 2017 Annual meeting of the American Society of Gene & Cell Therapy

Immunogenicity of Therapeutic Proteins. Steven J Swanson, Ph.D. Executive Director, Clinical Immunology

PLANNING FOR SUCCESS: A CMC STRATEGY FOR BIOSIMILARS

Comparing Droplet Digital PCR to Quantitative PCR: Evolving the Gene Therapy Viral Vector Analytical Paradigm

BIOSTATISTICAL METHODS

8. Clinical Trial Assessment Phase II

Development and challenges to monoclonal antibodies for passive immunization

Preclinical Development of Biologics: Case-by-case, so get off of my case!

New Hope For Serious Infections

Technical Guidance on Development of In Vitro Companion Diagnostics and Corresponding Therapeutic Products

Risk-based testing for anti-drug neutralizing antibodies during development of biological therapeutics

Session 2 summary Designs & Methods. Pairwise comparisons approach. Dose finding approaches discussed: Guiding principles for good dose selection

Nonclinical Data to Support FIH Clinical Trials for Cancer Immunotherapies. Whitney S. Helms, PhD IOM, February 29,2016

Toxicology - Problem Drill 24: Toxicology Studies in Pharmaceutical Development

REIMAGINING DRUG DEVELOPMENT:

Overview of Biologics Testing and Evaluation: Regulatory Requirements and Expectations. Audrey Chang, PhD, Senior Director Development Services

NaNoplasmid TM. Platform SIZE MATTERS SMALLER IS BETTER

Engage with us on Twitter: #Molecule2Miracle

Juvenile toxicity studies with biopharmaceuticals : considerations and current practices

What s the difference? Challenges in pre-clinical development of biologics

Develop A Highly Similar" Biosimilar Compound: Lessons Learnt

Harmonizing clinical trials for Biogenerics. Dr. Akhilesh Sharma M.D.;C Clin. Research & P.V. (UCBC - USA & Luton - UK)

Recombinant, Insect Cell-Derived RSV Nanoparticle Vaccine

Investigations in Immune Suppression for Monoclonal Antibody Therapeutics

8 th Vaccine & ISV Congress October 2014 Philadelphia, USA

Global Development Challenges: Classical and Advanced Therapy Medicinal products

Outline. o Immunogenicity of therapeutic protein aggregates. o Clinical evidence. o Models to study the immunogenicity of aggregates

AME-133: A Next-Generation Anti-CD20 Engineered for Enhanced Killer Function

DepoVax TM : A novel delivery formulation for cancer immunotherapy and infectious disease vaccines

Momenta Pharmaceuticals, Inc. 36 th Annual J.P. Morgan Healthcare Conference

Notes from Round Table 5. January 26 and 27, 2016

Yodit Belew, MD Senior Medical Officer Division of Antiviral Products OAP/OND/CDER/FDA 1

NIAID Resources to Facilitate Medical Countermeasure Development

HSV-2 therapeutic vaccine program. Subunit vaccine candidates

Policy Position. Pharmacy-mediated interchangeability for Similar Biotherapeutic Products (SBPs)

May 9, Meeting Summary. Facilitating Antibacterial Drug Development

Issue 3: Policy Considerations for Different Product Types. Mark Zylstra April 22, 2015

BIOSTATISTICAL METHODS FOR TRANSLATIONAL & CLINICAL RESEARCH

Linker p. 177 Helper Lipid p. 178 Delivery to Target Cells p. 180 Cell Entry p. 182 Receptor-Mediated Uptake p. 182 Endosomai Release p.

Transcription:

Passive Immunization Trials to Inform Vaccine Design Points for Consideration from deliberations held at the August 8, 2014 workshop Contents I. Introduction... 2 II. Types of trials... 2 1. Therapeutic and cure applications... 2 2. Prevention trials... 2 a. Prevention of MTCT... 2 b. Prevention studies in adults... 3 3. Preclinical studies... 3 III. Expected information... 3 1. Proof of principle... 3 2. Establishing minimal level of neutralization needed for protection... 4 3. Other correlates of protection and information useful for vaccine design... 5 a. Breadth vs Potency... 5 b. Fab considerations... 5 c. Fc considerations... 5 IV. Gene-based Ab delivery... 6 V. Acknowledgements... 6 1

I. Introduction A number of research groups are working on passive immunization as an approach to prevent, treat, or cure HIV infection. It is often stated that these studies will inform preventive HIV vaccine research and development by 1) establishing a proof of principle that bnabs can prevent HIV infection; 2) setting minimal levels of neutralization required to prevent HIV infection; 3) providing additional correlates or other relevant information for vaccine design and testing. The Enterprise organized a workshop to review the current research plans in this area and to discuss what specific information relevant to the preventive HIV vaccine field can be gathered from such studies. This document summarizes the main points of discussion from that meeting. II. Types of trials 1. Therapeutic and cure applications There was a general agreement that therapeutic and cure efforts set a much higher bar for the effectiveness of passive immunization than would be required for prevention of infection. To treat or cure infection, antibodies should effectively suppress large numbers of virions already present in the body, while typically only one to two viruses establish infection. Antibody present at levels sufficient for 90% neutralization in vitro can be expected to translate into 60-70% efficacy in preventing transmission. Therefore, therapeutic applications may benefit from antibodies that are highly potent against the specific virus being treated, while prevention may be better accomplished with antibodies that have the broadest coverage. Using antibodies in combination with antiviral drug therapy, an approach proposed by some groups, would make it difficult to extrapolate how effective an antibody can be on its own. Moreover, the use of antibodies in therapeutic or cure settings may require different specificity and/or functionality of antibodies than those required for prevention, also calling into question whether information from such trials can be informative for preventive vaccine research. Most participants felt that demonstrating an efficacy of a bnab in an infected human would provide additional line of evidence that neutralization or effector functions observed in vivo are translatable to in vivo settings. 2. Prevention trials a. Prevention of MTCT Due to the well-defined period of infection risk and the small doses needed to establish the desired concentration of Ab per kg of weight in an infant, MTCT settings present a unique opportunity to use the small-scale manufacturing batches of Ab to study the efficacy of passive immunization in preventing HIV transmission. As a result, these studies are likely to be the first to provide efficacy data, which may happen as soon as 2018. Nevertheless, the confounding factors for applying information obtained from this approach to vaccine research are as follows: 1) passive immunization would not be used on its own, but in addition to the existing standard of care; and 2

2) the biology of MTCT transmission is different from the predominantly sexual transmission in adults and may require different (lower or higher) antibody levels for protection. b. Prevention studies in adults At the moment, clinical studies in adults are limited to Phase I trials that aim to investigate safety and pharmacokinetic properties of Abs in healthy or infected adults. These studies, while critical for future clinical development of antibodies, are not very informative for the HIV vaccine field. Prevention efficacy studies in high-risk adults are being considered, but the data will likely not be available until at least 2020. On the positive side, long timelines mean that the field still has the opportunity to plan ahead and consider how such studies can be performed to better inform HIV vaccine research. 3. Preclinical studies Because bnabs are specific for HIV Env, they have to be tested in preclinical models that use HIV or SHIV, which have been limited in the diversity of available viruses or in how well they approximate human transmission and disease. Infection of humanized mice with HIV has been instrumental in early-stage studies to evaluate and down-select antibody candidates for further development. New SHIV models are being actively developed that hold promise for studying effects of bnabs in vivo, although (just like the current models) they will still be limited to a single antibody administration due to antiantibody responses by the animal s immune system. Nevertheless, these models will be critical for downselecting candidates from the wide variety of available individual antibodies and their combinations they can be used to detect large differences in efficacy, evaluate PK/PD properties, and detect synergistic effects within combinations. III. Expected information 1. Proof of principle For many existing vaccines it is believed that neutralizing antibodies are responsible for protection, but it is not known whether this belief can be extrapolated to HIV. A definitive proof that neutralizing antibodies can provide protection against HIV in the absence of any other anti-hiv responses would be valuable. However, data from animal models already strongly suggest that bnabs can protect against infection and most researchers agree that if bnabs were elicited via vaccination in humans, they would prove efficacious. Therefore, while such proof of principle will be valuable, many participants felt that it would not have a dramatic impact on the field. Moreover, some argued that findings from passive immunization studies cannot be directly translated to vaccine research because these studies depend upon high titers of neutralizing antibodies established in the absence of any other anti-viral immune response in the body, which is not possible to accomplish via vaccination. Additional anti-viral immune responses may either contribute to protection, or they may reduce protection if, as some researchers argue, HIV-specific CD4 cells serve as effective target cells for the virus and promote infection. It was also pointed out that passive immunization studies may reveal some unexpected information about antibody activity in vivo. For example, if it s found that antibodies protect in vivo at levels that are substantially lower than those required to suppress the virus in vitro, it may help identify some alternative mechanisms of protection beyond those measure in in vitro neutralization assays. 3

2. Establishing minimal level of neutralization needed for protection Passive immunization trials could help define the quantitative relationship between the levels of neutralization observed in sera and the efficacy of protection, thus perhaps establishing goalposts for bnab-based vaccines. However, this simple concept requires careful consideration and planning if it is to be accomplished effectively. In order to define a specific level of neutralization as a correlate of protection, one needs to have measurable variability in both antibody levels and in efficacy of protection. As a result, the search for correlates in some cases may be at odds with product development goals. The objective of an efficacy trial is to maximize overall treatment efficacy, but to maximize the chances of defining a correlate, the trial should maximize the variability of treatment efficacy, while retaining reasonably high overall protection (50-70% is ideal). Correlates analysis also requires establishment of low-noise assays for measuring functions that one may expect to vary in the trial and planning for appropriate sample collection. Finally, trial design needs to be evaluated for statistical power needed to conduct the appropriate correlate analysis. Probably the most straightforward way to establish antibody concentration as a correlate of protection would be to administer antibodies in different doses and measure the resulting efficacy (see Fig on the right). However, several meeting participants raised the concern that administering antibodies in suboptimal concentration would be unethical. The issue was not extensively discussed at the meeting. Ab concentration Time Maintaining equipoise may be accomplished by comparing study arms with hard to predict relative efficacies. For example, as shown on the right, group A may receive large doses at longer intervals, while group B may receive smaller doses more frequently, both providing the same average antibody concentration, but group A having both higher or lower concentrations at certain times. Higher efficacy in group A would indicate that highest concentrations of Ab achieved in group B Time are less effective than the highest concentrations of Ab in group A. Alternatively, higher efficacy in group B would indicate that the lowest concentrations in group A are less effective than the lowest concentrations in group B. Other creative administration schedule variations may also help address this question, while preserving investigators equipoise. Ab concentration It was pointed out that even within a single arm antibody concentrations will vary over time and this variation may help determine the concentration required for protection. For example, dividing each administration period into High and Low periods, as shown on the right, may allow one to correlate average concentrations with observed efficacy during these periods. One challenge for this approach is that timing of HIV diagnosis should be sufficiently frequent and accurate to place each infection into one of the two periods, which may be as short as 1 week. Ab concentration H L H L H L H L H L Time Finally, the information on correlation between neutralization levels and transmission rates may come from analysis of the sensitivity of transmitted viruses to neutralization 4

by the tested antibody. Comparing phenotypes of transmitter/founder viruses isolated from volunteers in placebo and bnab arms may reveal a neutralization threshold below which sensitive viruses are not found in the bnab arm (but are still found in the placebo arm). The approach is in line with the neutralization sieve analysis proposed recently by David Montefiori. One caveat to this approach is the need to plan in advance for labor-intensive T/F virus reconstruction and neutralization assays. Another caveat is that for some of the bnabs, resistance of most viruses to neutralization can be described as all or nothing, while this analysis requires a 100000 continuous spectrum of sensitivities. Therefore, to inform vaccine design it may be useful to test bnabs that have a more gradual resistance profile in viral panels. In addition, a more classical sieve analysis may also identify viral signatures associated with breakthrough infections. To summarize, passive immunization studies may help establish the minimal level of neutralization required for protection, but this information will not be readily available unless researchers proactively plan for appropriate study design, necessary sampling, assays, and statistical power. 3. Other correlates of protection and information useful for vaccine design a. Breadth vs Potency Newly discovered bnabs vary both in the potency of viral inhibition and in the breadth of diversity of affected viruses. It may be informative to test whether an antibody with lower potency but wider breadth (such as PGT121 or 10-1074) will be more (or less) effective in vivo than a highly-potent antibody with a narrower breadth (such as VRC01 or 3BNC117). This information may help focus future efforts in bnab-based vaccine research. While the antibodies that are now going into the clinic do differ in these properties, that difference was not specifically considered in selecting the candidates for testing and there are no plans for head-to-head comparisons. b. Fab considerations It is conceivable that bnabs targeting different sites of the Env protein may have different protection efficacy in vivo even when they have similar neutralization potency and breadth in vitro. Such information would help guide immunogen selection for future vaccines. Among the current candidates going into the clinic, VRC01 and 3BNC117 target the CD4 binding site, while PG9 targets the glycan on the V1/V2 loops. In addition, comparing single antibodies to antibody combinations may provide information on synergistic effects of targeting multiple sites on Env. c. Fc considerations All three of the current candidates in clinical trials are of IgG1 subtype, although the exact sequences of the Fc portions are not identical. Fc-mediated functions may play an important role in protection via a variety of mechanisms such as ADCC, ADCVI and others, which are not well understood. However, for proper comparison and understanding of the role these functions may play in protection, it would be necessary to construct and compare antibodies that are specifically designed to answer these questions, e.g. by introducing targeted mutations that improve or abrogate these functions. Additional studies in animal models may be appropriate to generate and test hypotheses on the importance of Fc functions before clinical studies would be justified. Indeed, Nussenzweig s group observed that antibodies with mutations in Fc resulted in Reciprocal IC50 10000 1000 100 10 1 Placebo Protection level bnab 5

virus escape while the virus remained sensitive to the antibody in vitro. This work may help identify new mechanisms (or correlates) of protection. IV. Gene-based Ab delivery Overall, the same considerations described above apply to gene-based antibody delivery platforms as to the direct protein delivery. The biggest difference is that gene-based platforms provide more stable antibody concentrations. As a result, antibody concentration at the time of infection is much easier to measure in these settings. However, this can also be a downside because correlate analysis requires variability in antibody concentration in order to define the minimal required levels for protection. Thus, different dosing will be required for such analysis with gene-based platforms. V. Acknowledgements We thank all participants of the 2014 workshop Passive Immunization Trials to Inform Vaccine Design ; the full list of attendees can be found at http://www.vaccineenterprise.org/timely-topics/passive-immunization-trialsinform-hiv-vaccine-design The report was developed by Yegor Voronin with contributions by Peter Gilbert, Barney Graham, Nancy Haigwood, and Lynn Morris. 6